Sort by
Items per page

Send to

Choose Destination

Links from PubChem Compound

Items: 1 to 20 of 2736


Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.

Buda-Nowak A, Kucharz J, Dumnicka P, Kuzniewski M, Herman RM, Zygulska AL, Kusnierz-Cabala B.

Med Oncol. 2017 Apr;34(4):68. doi: 10.1007/s12032-017-0928-z. Epub 2017 Mar 25.


Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise: Role of Interstitial Sodium Accumulation?

Lankhorst S, Severs D, Markó L, Rakova N, Titze J, Müller DN, Danser AH, van den Meiracker AH.

Hypertension. 2017 May;69(5):919-926. doi: 10.1161/HYPERTENSIONAHA.116.08565. Epub 2017 Mar 20.


Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature.

Paix A, Waissi W, Antoni D, Adeduntan R, Noël G.

Cancer Radiother. 2017 Feb;21(1):55-59. doi: 10.1016/j.canrad.2016.09.012. Epub 2017 Feb 23. Review.


Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.

Randrup Hansen C, Grimm D, Bauer J, Wehland M, Magnusson NE.

Int J Mol Sci. 2017 Feb 21;18(2). pii: E461. doi: 10.3390/ijms18020461. Review.


MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.

Sheng Y, Ng CP, Lourie R, Shah ET, He Y, Wong KY, Seim I, Oancea I, Morais C, Jeffery PL, Hooper J, Gobe GC, McGuckin MA.

Int J Cancer. 2017 May 15;140(10):2351-2363. doi: 10.1002/ijc.30651. Epub 2017 Feb 28.


Synthesis of sericin-based conjugates by click chemistry: enhancement of sunitinib bioavailability and cell membrane permeation.

Scrivano L, Iacopetta D, Sinicropi MS, Saturnino C, Longo P, Parisi OI, Puoci F.

Drug Deliv. 2017 Nov;24(1):482-490. doi: 10.1080/10717544.2016.1267822.


Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.

Wang W, Zhou J, Zhao L, Chen S.

Biomed Pharmacother. 2017 Apr;88:985-990. doi: 10.1016/j.biopha.2017.01.135. Epub 2017 Feb 6.


Targeted Therapy for Metastatic Renal Cell Carcinoma.

Afriansyah A, Hamid AR, Mochtar CA, Umbas R.

Acta Med Indones. 2016 Oct;48(4):335-347. Review.


CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.

Haider MA, Vosough A, Khalvati F, Kiss A, Ganeshan B, Bjarnason GA.

Cancer Imaging. 2017 Jan 23;17(1):4. doi: 10.1186/s40644-017-0106-8.


Metastatic renal clear cell carcinoma to the rectum, lungs, ilium, and lymph nodes: A case report.

Zheng G, Li H, Li J, Zhang X, Zhang Y, Wu X.

Medicine (Baltimore). 2017 Jan;96(1):e5720. doi: 10.1097/MD.0000000000005720.


Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.

Wendel C, Campitiello M, Plastino F, Eid N, Hennequin L, Quétin P, Longo R.

Am J Case Rep. 2017 Jan 3;18:7-11.


A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.

Stubbs C, Bardoli AD, Afshar M, Pirrie S, Miscoria M, Wheeley I, Porfiri E.

Anticancer Res. 2017 Jan;37(1):253-259.


Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases.

Hamzaoui L, Medhioub M, Bouassida M, Mahmoudi M, El Bouchtili S, Ezzine H, Chelbi E, Touinsi H, Azouz MM.

Arab J Gastroenterol. 2016 Dec;17(4):185-187. doi: 10.1016/j.ajg.2016.11.001. Epub 2016 Dec 7.


Synthesis and Antitumor Activity of 5-Bromo-7-azaindolin-2-one Derivatives Containing a 2,4-Dimethyl-1H-pyrrole-3-carboxamide Moiety.

Zhang J, Shen W, Li X, Chai Y, Li S, Lv K, Guo H, Liu M.

Molecules. 2016 Dec 6;21(12). pii: E1674.


Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis.

Liu X, Fiocco M, Swen JJ, Guchelaar HJ.

Acta Oncol. 2017 Apr;56(4):582-589. doi: 10.1080/0284186X.2016.1265666. Epub 2016 Dec 7.


A novel PDGF receptor inhibitor-eluting stent attenuates in-stent neointima formation in a rabbit carotid model.

Huang C, Mei H, Zhou M, Zheng X.

Mol Med Rep. 2017 Jan;15(1):21-28. doi: 10.3892/mmr.2016.5986. Epub 2016 Dec 5.


EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.

Chang H, Sung JH, Moon SU, Kim HS, Kim JW, Lee JS.

Yonsei Med J. 2017 Jan;58(1):9-18. doi: 10.3349/ymj.2017.58.1.9.


Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.

Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR.

J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.


Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.

Nakai Y, Miyake M, Morizawa Y, Hori S, Tatsumi Y, Anai S, Onishi S, Tanaka N, Fujimoto K.

Oncol Rep. 2017 Jan;37(1):227-234. doi: 10.3892/or.2016.5232. Epub 2016 Nov 8.


Supplemental Content

Support Center